Please ensure Javascript is enabled for purposes of website accessibility

Why Insulet's Shares Are Rocketing 20.8% Higher Today

By Todd Campbell - Updated Aug 6, 2019 at 3:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The insulin pump maker's second-quarter financial results are sparking optimism.

What happened

After the release of second-quarter revenue results on Monday that were better than industry watchers were expecting, Insulet's (PODD 2.04%) shares were surging 20.8% higher at 2:45 p.m. EDT on Tuesday.

So what

More than 30 million Americans are diagnosed with diabetes, including more than 1 million people with type 1 diabetes who require constant blood sugar monitoring and regular dosing of insulin to delay disease progression.

A doctor holds a sign with the word diabetes written on it.


Historically, type 1 patients have used multiple daily fingersticks and insulin injections to manage their disease. Increasingly, these patients are shifting to continuous glucose monitors, such as those made by DexCom (DXCM 1.62%) or Abbott Labs (ABT 0.71%), and insulin pumps, such as those made by Insulet and Tandem Diabetes (TNDM -1.37%).

Unlike competing pumps, Insulet's insulin pump -- Omnipod -- is the only tubeless option available to patients. Omnipod users simply apply the device, which lasts 72 hours, to their skin, and then they control dosing via a separate handheld device.

In the second quarter, increasing adoption of Omnipod translated into Insulet revenue of $177.1 million, up 43% from the same quarter last year. Omnipod sales were $160.8 million, an increase of 51% year over year. The remaining sales were associated with using medicines other than insulin in Omnipod pumps.

Gross margin was 65.7% in the second quarter, down 30 basis points year over year, because of investments in a new automated manufacturing line. The dip in margin was more than made up for by sales growth and controlled operating expenses, so Insulet's net income in the period improved to $1.4 million from a loss of $1.7 million one year ago.

Now what

The better top-line performance has prompted management to raise its full-year sales forecast to at least $700 million from prior guidance for at least $667 million. If it delivers on that target, it would represent a 24% increase from 2018.

Further out, the company continues to develop its Horizon automated insulin system, which automatically doses insulin based on readings from DexCom's continuous glucose monitors. Earlier this year, Insulet released data suggesting Horizon may help keep patient's within their desired blood glucose range more often. A Horizon launch is planned for late in 2020 after clinical trials wrap up.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Insulet Corporation Stock Quote
Insulet Corporation
$198.72 (2.04%) $3.98
Abbott Laboratories Stock Quote
Abbott Laboratories
$113.24 (0.71%) $0.80
DexCom, Inc. Stock Quote
DexCom, Inc.
$321.23 (1.62%) $5.11
Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$71.99 (-1.37%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.